Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2404-2412

  Allott, Emma H ^a,b,c   Howard, Lauren E ^a,c   Song, Hai Jun ^a,c   Sourbeer, Katharine N ^a,c   Koontz, Bridget F ^a   Salama, Joseph K ^a,c   Freedland, Stephen J ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGGRESSIVE PROSTATE CANCER; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; BRACHYTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CROSS-SECTIONAL STUDY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HEALTH DISPARITY; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE; WEIGHT GAIN; ADIPOSE TISSUE; COMPLICATION; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR; TISSUE DISTRIBUTION;

ADIPOSE TISSUE; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; HUMANS; MALE; OBESITY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; TISSUE DISTRIBUTION;

EID: 84920145304     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0236     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9.
3. Farrell J, Petrovics G, McLeod DG, Srivastava S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci 2013;14:15510-31.
4. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-9.
5. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
6. Carroll JF, Fulda KG, Chiapa AL, Rodriquez M, Phelps DR, Cardarelli KM, et al. Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity 2009;17:1420-7.
7. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr 1999;69:381-7.
8. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 2013;21:E439-47.
9. De Nunzio C, Albisinni S, Freedland SJ, Miano L, Cindolo L, Finazzi Agro E, et al. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study. Urol Oncol 2013;31:997-1002.
10. Nemesure B, Wu SY, Hennis A, Leske MC. Central adiposity and prostate cancer in a black population. Cancer Epidemiol Biomarkers Prev 2012;21:851-8.
11. van Roermund JG, Hinnen KA, Tolman CJ, Bol GH, Witjes JA, Bosch JL, et al. Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients. BJU Int 2011;107:1775-9.
12. Chang SH, Pollack LM, Colditz GA. Life years lost associated with obesity-related diseases for U.S. non-smoking adults. PLoS ONE 2013;8:e66550.
13. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-94.
14. van Roermund JG, Bol GH, Witjes JA, Ruud Bosch JL, Kiemeney LA, van Vulpen M. Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness. World J Urol 2010;28:699-704.
15. Zilli T, Nguyen TV, Bahary JP, Chagnon M, Dufresne A, Taussky D. Prognostic impact of abdominal adiposity, waist circumference and body mass index in patients with intermediate-risk prostate cancer treated with radiotherapy. Int J Obes 2011;35:1421-6.
16. Ciudin A, Salvador R, Budoy A, Ciudin A, Spinu C, Diaconu MG, et al. Measurement of waist circumference for retrospective studies - prospective validation of use of CT images to assess abdominal circumference. Endocrinol Nutr 2014;61:147-52.
17. Sousa AS, de Sousa OL, Amaral TF. The effect of posture on body circumferences in older adults. J Hum Nutr Diet 2014;27:80-7.
18. Waninge A, Ligthart KA, Kramer J, Hoeve S, van der Schans CP, Haisma HH. Measuring waist circumference in disabled adults. Res Dev Disabil 2010;31:839-47.
19. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439-45.
20. Caire AA, Sun L, Polascik TJ, Albala DM, Moul JW. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU Int 2010;106:1157-60.
21. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008;17:3252-61.
22. Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol 2007;178:1939-44.
23. Kim HS, Moreira DM, Smith MR, Presti JC Jr, Aronson WJ, Terris MK, et al. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 2011;107:924-8.
24. Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2009;115:5263-71.
25. Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC, Bensen JT, et al. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiol Biomarkers Prev 2011;20:844-53.
26. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003.
27. Qu YY, Dai B, Kong YY, Chang K, Ye DW, Yao XD, et al. Influence of obesity on localized prostate cancer patients treated with radical prostatectomy. Asian J Androl 2013;15:747-52.
28. Zilli T, Chagnon M, Van Nguyen T, Bahary JP, Guay JP, Dufresne A, et al. Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic fi ndings in patients treated with radiotherapy for localized prostate cancer. Cancer 2010;116:5650-8.
29. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007;109:875-81.
30. Carroll JF, Chiapa AL, Rodriquez M, Phelps DR, Cardarelli KM, Vishwanatha JK, et al. Visceral fat, waist circumference, and BMI: impact of race/ethnicity. Obesity 2008;16:600-7.
31. Demerath EW. Causes and consequences of human variation in visceral adiposity. Am J Clin Nutr 2010;91:1-2.
32. Gardener H, Crisby M, Sjoberg C, Hudson B, Goldberg R, Mendez AJ, et al. Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. Metab Syndr Relat Disord 2013;11:46-55.
33. Kim CX, Bailey KR, Klee GG, Ellington AA, Liu G, Mosley TH, et al. Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. PLoS ONE 2010;5:e9065.
34. Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 2009;182:1621-7.
35. Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res 2012;31:32.
36. Toren P, Venkateswaran V. Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment. Clin Genitourin Cancer 2014;12:21-6.
37. Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008;102:44-7.
38. Timilshina N, Breunis H, Alibhai SM. Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer. J Urol 2012;188:2183-8.
39. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.